2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board

Affiliations

¹ Division of Urology, Department of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.
² Division of Urology, Woodstock General Hospital, Woodstock, ON , Canada.
³ Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
⁴ Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON , Canada.
⁵ Division of Urology, Department of Surgery, Université Laval, Quebec, QC, Canada.
⁶ Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON , Canada.
⁷ Division of Urology, Department of Surgery McMaster University, Hamilton, ON , Canada.
⁸ Department of Urology, Queen's University, Kingston General Hospital, Kingston, ON , Canada.
⁹ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Division of Urology, Department of Surgery, Saint John Regional Hospital, Dalhousie University, Saint John, NB, Canada.
¹¹ Department of Urology, QEII Health Sciences Centre, Dalhousie University, Halifax, NS , Canada.
¹² Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada.

PMID: 37310905
PMCID: PMC10263289
DOI: 10.5489/cuaj.8389

2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board

Patrick O Richard et al. Can Urol Assoc J. 2023 Jun.

. 2023 Jun;17(6):162-174.

doi: 10.5489/cuaj.8389.

Authors

Affiliations

¹ Division of Urology, Department of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.
² Division of Urology, Woodstock General Hospital, Woodstock, ON , Canada.
³ Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
⁴ Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON , Canada.
⁵ Division of Urology, Department of Surgery, Université Laval, Quebec, QC, Canada.
⁶ Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON , Canada.
⁷ Division of Urology, Department of Surgery McMaster University, Hamilton, ON , Canada.
⁸ Department of Urology, Queen's University, Kingston General Hospital, Kingston, ON , Canada.
⁹ Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Division of Urology, Department of Surgery, Saint John Regional Hospital, Dalhousie University, Saint John, NB, Canada.
¹¹ Department of Urology, QEII Health Sciences Centre, Dalhousie University, Halifax, NS , Canada.
¹² Division of Urology, Department of Surgery, McGill University, Montreal, QC, Canada.

PMID: 37310905
PMCID: PMC10263289
DOI: 10.5489/cuaj.8389

No abstract available

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS : Dr. Richard has been an advisory board member for Bayer, Janssen, and Sanofi; and a speakers’ bureau member for Abbvie, Amgen, Astellas, Ferring, and Janssen. Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Breau has been an advisory board member for Ferring (bladder cancer). Dr. Jewett has been an advisory board member for and received payment from Sesen Bio and Theralase Technologies Ltd. Dr. Kapoor held consultant or advisory roles with Amgen, Bristol-Myers Squibb, Eisai, Ipsen, Janssen Oncology, Merck, Novartis, and Pfizer; and received institutional research funding from Bristol-Myers Squibb. Dr. Pouliot has been an advisory board member for and received payment or grants from Amgen, Astellas, Astra Zeneca, Bayer, Janssen, Merck, Novartis, TerSera, and Tolmar; holds investments in Allogene Therapeutics; and has participated in clinical trials supported by CUOG and Kidney Cancer Canada. Dr. Leveridge has participated in advisory board meetings for Bayer and Pfizer; and has received honoraria from Bayer, Janssen, and Pfizer. Dr. So has been an advisory board member for Abbvie, Amgen, Bayer, Ferring, Janssen, Merck, and TerSera. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen, Pfizer, Roche, Sanofi, and Tolmar; has received honoraria/grants from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, TerSera, and Tolmar; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. Dr. Tanguay has received honoraria from Pfizer, Roche Canada, and Sanofi; and has held consulting or advisory roles with BMS , Merck, Pfizer, Roche Canada, and Sanofi. The remaining authors do not report any competing personal or financial interests related to this work.

Comment on

page 175

Cited by

Updated cystic renal lesions guideline: A springboard for shared decision-making.
Martin PR, Black PC, Jammal MP, Kassouf W, Siemens DR, Aprikian A. Martin PR, et al. Can Urol Assoc J. 2023 Jun;17(6):175. doi: 10.5489/cuaj.8388. Can Urol Assoc J. 2023. PMID: 37310907 Free PMC article. No abstract available.
Rapid recommendations: Updates from 2023 guidelines: part 2.
O'Toole D. O'Toole D. Can Fam Physician. 2024 Oct;70(10):632-633. doi: 10.46747/cfp.7010632. Can Fam Physician. 2024. PMID: 39406425 Free PMC article. No abstract available.
Assessing the methodologic heterogeneity of Canadian Urological Association guidelines Adoption of the GRADE approach (2018-2023).
Ding M, Gandhi V, Gonzalez-Padilla DA, Dahm P. Ding M, et al. Can Urol Assoc J. 2025 Jun;19(6):173-180. doi: 10.5489/cuaj.8926. Can Urol Assoc J. 2025. PMID: 40031951 Free PMC article.

References

1. Volpe A, Panzarella T, Rendon R, et al. The natural history of incidentally detected small renal masses. Cancer. 2004;100:738–45. doi: 10.1002/cncr.20025. - DOI - PubMed
1. Marumo K, Horiguchi Y, Nakagawa K, et al. Incidence and growth pattern of simple cysts of the kidney in patients with asymptomatic microscopic hematuria. Int J Urol. 2003;10:63–7. doi: 10.1046/j.1442-2042.2003.00577.x. - DOI - PubMed
1. Pichler M, Hutterer GC, Chromecki TF, et al. Histologic tumor necrosis is an independent prognostic indicator for clear-cell and papillary renal cell carcinoma. Am J Clin Pathol. 2012;137:283–9. doi: 10.1309/AJCPLBK9L9KDYQZP. - DOI - PubMed
1. Richard PO, Violette PD, Jewett MAS, et al. CUA guideline on the management of cystic renal lesions. Can Urol Assoc J. 2017;11:E66–73. doi: 10.5489/cuaj.4484. - DOI - PMC - PubMed
1. Bosniak M. The current radiological approach to renal cysts. Radiology. 1986;158:1–10. doi: 10.1148/radiology.158.1.3510019. - DOI - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources